Last reviewed · How we verify
SULTAMICILLIN
Sultamicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Sultamicillin is a small molecule antibiotic in the sultamicillin class, originally developed by an unknown entity. Its current owner is also unknown. The exact target of sultamicillin is not specified, but it is used to treat various bacterial infections. The commercial status of sultamicillin is unclear, with unknown patent status and generic manufacturers. Key safety considerations are also unknown.
At a glance
| Generic name | SULTAMICILLIN |
|---|---|
| Drug class | sultamicillin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells are like buildings, and bacteria are like construction workers. Sultamicillin stops the construction workers from building new walls, causing the bacteria to die. This is because sultamicillin blocks the enzymes that help bacteria build their cell walls.
Approved indications
Common side effects
- Autoimmune dermatitis
Key clinical trials
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients (NA)
- Therapeutic Options for CRAB (PHASE4)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SULTAMICILLIN CI brief — competitive landscape report
- SULTAMICILLIN updates RSS · CI watch RSS